First point-of-care PSA test for prostate cancer detection

Alexa R. Meyer; Michael A. Gorin

doi:10.1038/s41585-019-0179-1

First point-of-care PSA test for prostate cancer detection

Alexa R. Meyer
, Michael A. Gorin

Research output: Contribution to journal › Comment/debate

28 Scopus citations

Abstract

The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.

Original language	English
Pages (from-to)	332-333
Number of pages	2
Journal	Nature Reviews Urology
Volume	16
Issue number	6
DOIs	https://doi.org/10.1038/s41585-019-0179-1
State	Published - 1 Jun 2019
Externally published	Yes

Access to Document

10.1038/s41585-019-0179-1

Cite this

@article{43c1ee37bfd847e6b9e3d63f2dab7b71,

title = "First point-of-care PSA test for prostate cancer detection",

abstract = "The FDA{\textquoteright}s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.",

author = "Meyer, \{Alexa R.\} and Gorin, \{Michael A.\}",

note = "Publisher Copyright: {\textcopyright} 2019, Springer Nature Limited.",

year = "2019",

month = jun,

day = "1",

doi = "10.1038/s41585-019-0179-1",

language = "English",

volume = "16",

pages = "332--333",

journal = "Nature Reviews Urology",

issn = "1759-4812",

publisher = "Nature Research",

number = "6",

}

TY - JOUR

T1 - First point-of-care PSA test for prostate cancer detection

AU - Meyer, Alexa R.

AU - Gorin, Michael A.

PY - 2019/6/1

Y1 - 2019/6/1

N2 - The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.

AB - The FDA’s approval of the first point-of-care total PSA test for prostate cancer has the potential to improve patient care by streamlining PSA testing. However, a Clinical Laboratory Improvement Amendments waiver is needed before this test can be fully integrated into clinical care.

UR - https://www.scopus.com/pages/publications/85063986481

U2 - 10.1038/s41585-019-0179-1

DO - 10.1038/s41585-019-0179-1

M3 - Comment/debate

C2 - 30948842

AN - SCOPUS:85063986481

SN - 1759-4812

VL - 16

SP - 332

EP - 333

JO - Nature Reviews Urology

JF - Nature Reviews Urology

IS - 6

ER -

First point-of-care PSA test for prostate cancer detection

Abstract

Access to Document

Fingerprint

Cite this